Posted inInteresting Papers
Faricimab Shows Similar Efficacy and Durability to Aflibercept for Neovascular Age-Related Macular Degeneration (nAMD)
This study compared faricimab and aflibercept for neovascular age-related macular degeneration (nAMD) over two years. The key findings showed that both drugs resulted in similar vision improvements. However, faricimab allowed for less frequent injections, with most patients extending their treatment intervals to 12 or 16 weeks by the second year. The safety of both drugs was comparable. The study suggests faricimab could be an effective and more convenient alternative to aflibercept for nAMD treatment, although further long-term research is warranted.



















